Current tumor necrosis factor-α inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 32, Issue 9, 2005, Pages 1662-1665

  Liang, George C ^a,b   Cordero, Magaly ^a   Dyer, Alan ^a   Chang, Rowland W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b M300   (United States)

Author keywords

Cross sectional study; Remission rates; Rheumatoid arthritis; TNF inhibitor; Treatment

Indexed keywords

ANTIRHEUMATIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; GENDER; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROBABILITY; RACE; REMISSION; RHEUMATOID ARTHRITIS;

ADULT; AGED; AMBULATORY CARE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PAIN MEASUREMENT; PROBABILITY; RANGE OF MOTION, ARTICULAR; RECOVERY OF FUNCTION; REFERENCE VALUES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 24944575156     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: A randomized controlled trial. Ann Intern Med 1999;130:478-86.
2. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
3. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
4. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 2003;48:35-45.
5. Pinals RS, Masi AT, Larsen RA, et al. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
6. Klareskog L, van der Heijde D, de Jager J, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363:675-81.
7. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
8. Van der Heijde DMFM, van't Hof MA, van Riel PLCM, et al. A comparison of validity of single variables and composed indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177-81.
9. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol 1985;12:234-52.
10. O'Dell J, Paulsen G, Haire C, et al. Combination DMARD therapy with methotrexate (M)-sulfasalazine (S)-hydroxychloroquine (H) in rheumatoid arthritis (RA): continued efficacy with minimal toxicity at 5 years [abstract]. Arthritis Rheum 1998;41 Suppl:S132.
11. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. Lancet 1999;353:1568-73.
12. Möttönen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease- modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
13. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004;50:36-42.
14. US Food and Drug Administration. Guidance for industry. Clinical development programs for drugs, devices and biological products for the treatment of rheumatoid arthritis [Internet]. US Department of Health and Human Services, FDA, Feb 1999 [cited 2003 September 25]. Available from: http://www.fda.gov./cber/gdlns/rheumcln.htm.